PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023
The enrollment is targeted to start by the end of 2023 and the first study results are expected in mid-2024.
- The enrollment is targeted to start by the end of 2023 and the first study results are expected in mid-2024.
- Key financial figures for the first nine months of 2023 compared with the same period of the previous year are summarized below.
- In the context of the Erytech-Pherecydes merger, PHAXIAM’s consolidated financial statements in IFRS standards include ex-Pherecydes financial results as from the date of the merger, i.e.
- Consequently, PHAXIAM’s P&L information for the first 9 months of 2023 include 9 months of ex-Erytech activities and ex-Pherecydes activities since June 23, 2023.